Mondello P - Search Results

1

Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.

Ninkovic M, Fiegl M, Mian M, Mondello P, Kocher F, Waldthaler C, Verdorfer I, Steurer M, Gastl G, Pircher A. Ninkovic M, et al. Among authors: mondello p. Anticancer Res. 2015 Sep;35(9):5129-39. Anticancer Res. 2015. PMID: 26254418

2

90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.

Mondello P, Pitini V, Arrigo C, Derenzini E, Mian M. Mondello P, et al. Anticancer Res. 2014 Sep;34(9):5121-5. Anticancer Res. 2014. PMID: 25202102 Free article.

3

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease.

Mondello P, Mian M, Arrigo C, Pitini V. Mondello P, et al. Springerplus. 2014 Jul 7;3:342. doi: 10.1186/2193-1801-3-342. eCollection 2014. Springerplus. 2014. PMID: 25045615 Free PMC article.

4

Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?

Mondello P, Steiner N, Wasle I, Pitini V, Mian M. Mondello P, et al. Anticancer Res. 2014 Nov;34(11):6701-4. Anticancer Res. 2014. PMID: 25368277

5

Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.

Wasle I, Gamerith G, Kocher F, Mondello P, Jaeger T, Walder A, Auberger J, Melchardt T, Linkesch W, Fiegl M, Mian M. Wasle I, et al. Among authors: mondello p. Ann Hematol. 2015 Apr;94(4):593-601. doi: 10.1007/s00277-014-2250-6. Epub 2014 Nov 13. Ann Hematol. 2015. PMID: 25387663

6

Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?

Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T, Marabese A, Mondello P, Patriarca F, Pizzolo G, Semenzato G, Cortelazzo S, Zambello R. Mian M, et al. Among authors: mondello p. Anticancer Res. 2016 Mar;36(3):1059-65. Anticancer Res. 2016. PMID: 26976998

7

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M. Mondello P, et al. Ann Hematol. 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22. Ann Hematol. 2016. PMID: 27103007

8

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M. Mondello P, et al. Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9. Oncologist. 2018. PMID: 29317554 Free PMC article.

9

Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.

Mondello P, Mian M. Mondello P, et al. Hematol Oncol. 2019 Oct;37(4):333-344. doi: 10.1002/hon.2613. Epub 2019 Apr 26. Hematol Oncol. 2019. PMID: 30938848 Review.

10

R-CHOP versus R-COMP: are they really equally effective?

Mian M, Wasle I, Gamerith G, Mondello P, Melchardt T, Jäger T, Linkesch W, Fiegl M. Mian M, et al. Among authors: mondello p. Clin Oncol (R Coll Radiol). 2014 Oct;26(10):648-52. doi: 10.1016/j.clon.2014.05.012. Epub 2014 Jun 12. Clin Oncol (R Coll Radiol). 2014. PMID: 24929649

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters